Changing How We Treat Relapsed/Refractory Hairy Cell Leukemia

Most patients with hairy cell leukemia (HCL) will eventually relapse following first-line purine analogue therapy, and some will develop purine analogue–refractory disease. Targeted therapies have improved outcomes for these patients with difficult-to-treat disease. Take this opportunity to deepen your understanding of current and evolving best practices for the treatment of patients with relapsed/refractory HCL.
Farhad Ravandi, MD

Downloadable Slideset

Farhad Ravandi, MD, examines evolving new approaches to hairy cell leukemia, including the antibody-drug conjugate moxetumomab pasudotox, BRAF inhibitors, and combination regimens.

Farhad Ravandi, MD Released: April 24, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue